Menu

盐酸缬更昔洛韦片可治疗什么病症呢?

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

It is an oral anti-cytomegalovirus infection drug that combines the advantages of oral administration and intravenous injection. It can effectively prevent and treat cytomegalovirus infection through correct oral administration every day, and significantly improve the patient's quality of life and long-term survival rate.

Valganciclovir Hydrochloride Tablets can treat the following symptoms: Prevention of cytomegalovirus (CMV) in high-risk adult kidney, heart, and pancreas transplant patients (donor CMV seropositive/recipient CMV seronegative). Prevention of cytomegalovirus (CMV) in high-risk children with kidney transplantation (4 months to 16 years old) and heart transplantation (1 month to 16 years old). Cytomegalovirus Retinitis, Treatment (AIDS-Related): Treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).

Adult patients should use valamciclovir hydrochloride tablets rather than valamciclovir hydrochloride oral solution. Oral solutions and tablets should be taken with food. Valaciclovir hydrochloride tablets should not be broken or crushed. Before dispensing the medication to the patient, the pharmacist must prepare an oral solution (50 mg/ml) with valamciclovir hydrochloride.

Recommended doses for adults with normal renal function are as follows:

Treatment of induction of cytomegalovirus retinitis: The recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days.

Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily.

Cytomegalovirus prophylaxis: For adult patients who have received a heart or kidney-pancreas transplant, the recommended dose is 900 mg orally once daily starting within 10 days of transplantation and continuing until 100 days after transplantation.

For adult patients who have received a kidney transplant, the recommended dose is 900 mg taken orally once daily starting within 10 days after transplantation and until 200 days after transplantation.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。